Ofatumumab versus Teriflunomide in Multiple Sclerosis

Hauser, SL; Bar-Or, A; Cohen, JA; Comi, G; Correale, J; Coyle, PK; Cross, AH; de Seze, J; Leppert, D; Montalban, X; Selmaj, K; Wiendl, H; Kerloeguen, C; Willi, R; Li, B; Kakarieka, A; Tomic, D; Goodyear, A; Pingili, R; Haring, DA; Ramanathan, K; Merschhemke, M; Kappos, L

Hauser, SL (corresponding author), Univ Calif San Francisco, Dept Neurol, UCSF Weill Inst Neurosci, 675 Nelson Rising Ln, San Francisco, CA 94158 USA.; Kappos, L (corresponding author), Univ Hosp Basel, Neurol Clin & Policlin, Dept Med, Petersgraben 4, CH-4031 Basel, Switzerland.; Kappos, L (corresponding author), Univ Hosp Basel, Neurol Clin & Policlin, Dept Clin Res, Petersgraben 4, CH-4031 Basel, Switzerland.; Kappos, L (corresponding author), Univ Hosp Basel, Neurol Clin & Policlin, Dept Biomed, Petersgraben 4, CH-4031 Basel, Switzerland.; Kappos, L (corresponding author), Univ Hosp Basel, Neurol Clin & Policlin, Dept Biomed Engn, Petersgraben 4, CH-4031 Basel, Switzerland.

NEW ENGLAND JOURNAL OF MEDICINE, 2020; 383 (6): 546

Abstract

BackgroundOfatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synth......

Full Text Link